Betadine Irrigation in Cesarean Section

August 12, 2016 updated by: Roberto Angioli, Campus Bio-Medico University

May Betadine Improve Cesarean Section Outcomes?

The purpose of this study was to evaluate, for the first time in Literature, the effects of betadine washing versus normal saline washing after uterine closure in women undergoing cesarean section (CS) at ≥36 gestational weeks in terms of post CS infections, complication, fever and pain.

Study Overview

Status

Completed

Detailed Description

This was a single-centre randomized controlled trial performed at Department of Obstetrics and Gynecology of San Camillo Hospital of Rome. The protocol was approved by the Internal Review Board. All women having a cesarean section (CS) were eligible for recruitment unless there was suspected or known allergy to iodine. The study was widely publicized around obstetrics unit and all women were provided antenatally with a brief statement regarding the study. The study was presented to women as part of hospital initiative to reduce postoperative infections and to improve postoperative recovery. Consent was obtained from all women at the time of consenting for CS.

Background was recorded for each patient: maternal age, gestational week at delivery, BMI, and pregnancy complication; plural fetal pregnancies, premature rupture of membranes, placenta previa and pre-eclampsia. The investigators recorded the type of cesarean procedure, elective (scheduled operations) or urgent (patients in labor and maternal or fetal emergent indication), mean surgical time to perform CS.

In Literature, povidone-iodine irrigation has been demonstrated to be a simple and inexpensive solution with the potential to prevent surgical site infection , which can also reduce the incidence of intra-abdominal infectious complications when used as an intraperitoneal irrigant in patients undergoing bacterially-contaminated surgical procedures, i.e. orthopedic, general surgery, oncologic surgery. Therefore, the investigators aimed to test its use in CS.

Patients were intra-operatively randomized to receive intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline or with only normal saline solution. Randomization to 'Betadine' or 'no Betadine' group was performed using sequentially numbered sealed opaque envelopes that contained the allocation. The allocation was prepared using computer generated list of random numbers using a variable block of 10 and performed by a staff members, part of the clinical team. After all layers were sutured and just prior to starting skin closure, the envelope with the allocation was opened by one of the theatre nurse.

All CS were generally performed under spinal anesthesia by the specialist obstetricians, credentialed trainee registrars or by juniors in the presence of a specialist obstetrician using the modified Misgav Ladach surgical technique.

An abdominal opening was made through a straight transverse incision, which was placed 3-4 cm above the symphysis. The subcutaneous tissue was left untouched apart from the midline. The rectus sheath was separated along its fibers and the rectus muscles separated by pulling. Stretching with index fingers opened the peritoneum and the uterus was opened with an index finger. The hole was enlarged between the index finger of one hand and the thumb of the other.

Single-layer closure of the uterine incision was performed as follows: a holding Vicryl-0 was placed in the left corner to stabilize and define the demarcation of the suture line. A continuous non-locking stitch beginning at the right corner was used, closing the whole thickness of the uterine wall, excluding the decidual layer, in a cranial/caudal position. Additional single sutures were added for hemostasis if required. Routinely exteriorization of the uterus was not performed. The visceral and parietal peritoneal layers were left open and the rectus muscle was not stitched. The rectus sheath was stitched with a continuous non-locking Vicryl-0 and the subdermal space was closed in all patients. All patients had preoperative exams not longer than 4 weeks prior the CS and received prophylactic intravenous antibiotics (amoxicillin 2 g and metronidazole 1 g) preoperatively to reduce the rate of wound infection. In addition, all patients received oxytocin intravenous during CS and 20 IU was administered by an intravenous drip running post surgical procedure. All patients were encouraged to start breastfeeding during early postoperative care, supported by a midwife and by a nurse specialized in newborn care after admission to the maternity ward.

Post CS infections included:

  • Postpartum endometritis: defined as a clinical diagnosis, usually involving fever, uterine fundal tenderness, or purulent lochia requiring antibiotic therapy.
  • Postoperative wound infection: defined as erythema, tenderness, purulent drainage from the incision site, with or without fever, requiring antibiotic therapy.
  • Postoperative fever: defined as greater than 38 degrees C or 100.4 degrees F.
  • Postoperative wound seroma or hematoma: defined as collection of serous fluid or blood/clot in the subcutaneous area of the incision.
  • Composite wound complications: defined as the presence of any one of the following: wound infection, seroma, hematoma, separation.

Patients were examined during daily rounds whilst in hospital about intestinal recanalization, postoperative mobilization, postoperative 24h post CS pain and wounds. Preoperative and postoperative exams, presence of fever or any symptoms have been accurately registered.

After discharge from the hospital, the women were sent a letter with addressed return envelope to report any post CS problems at four weeks after surgery as part of hospital surveillance policy. Charts of all women readmitted for any reason were reviewed. Differences between 'Betadine' and 'no Betadine' groups were assessed using chi square for categorical data test. Fisher's exact test was used where there were 5 or fewer counts within a category and t-test for continuous data. Relative risk (RR) and the corresponding 95% confidence interval (CI) were calculated. A P value of <0.05 was considered statistically significant.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rome, Italy, 00128
        • Campus Bio-Medico of Rome

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • women aged 18-50 years
  • planned or urgent cesarean section (CS)
  • gestational age > 36 weeks
  • written informed consent

Exclusion criteria:

  • suspected or known allergy to iodine

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Betadine Group
Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
Other: No Betadine Group
Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of postoperative infections
Time Frame: up to 20 days after cesarean section
postoperative infections expressed in number of patients with postoperative infections, such as endometritis or wood infections up to 20 days after cesarean section
up to 20 days after cesarean section

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Roberto Angioli, Professor, Campus Bio-Medico University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2015

Primary Completion (Actual)

March 1, 2016

Study Completion (Actual)

June 1, 2016

Study Registration Dates

First Submitted

July 27, 2016

First Submitted That Met QC Criteria

August 12, 2016

First Posted (Estimate)

August 15, 2016

Study Record Updates

Last Update Posted (Estimate)

August 15, 2016

Last Update Submitted That Met QC Criteria

August 12, 2016

Last Verified

July 1, 2016

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infection; Cesarean Section

Clinical Trials on betadine group

3
Subscribe